{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-005446","form_type":"8-K","ticker":"RAPP","cik":"0002012593","company_name":"Rapport Therapeutics, Inc.","filed_at":"2026-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.988215+00:00","generated_at":"2026-05-16T11:26:29.194699+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rapport accelerates Phase 3 start for RAP-219 in focal seizures to Q2 2026; expands epilepsy portfolio into PGTCS","bullets":["Phase 3 program for RAP-219 in focal onset seizures accelerated to Q2 2026 (from Q3) after FDA End-of-Phase 2 meeting.","New epilepsy program in primary generalized tonic-clonic seizures (PGTCS); Phase 3 trial planned H1 2027.","FDA removed clinical hold on DPNP IND; Rapport defers further DPNP investment to prioritize α6β4 program.","$513M cash, cash equivalents and short-term investments as of Q3 2025; expected to fund operations into H2 2029.","Phase 2 bipolar mania trial on track for H1 2027 topline; long-acting injectable IND-enabling activities start Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-005446","json":"https://secwatch.observer/filing/0001193125-26-005446.json","markdown":"https://secwatch.observer/filing/0001193125-26-005446.md","text":"https://secwatch.observer/filing/0001193125-26-005446.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526005446/0001193125-26-005446-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526005446/rapp-20260107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:26:29.194699+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}